Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159


Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV.

J Clin Invest. 2000 Dec;106(12):1489-99.


Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV.

J Cereb Blood Flow Metab. 2007 May;27(5):909-18. Epub 2006 Nov 1.


Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Qosa H, Abuasal BS, Romero IA, Weksler B, Couraud PO, Keller JN, Kaddoumi A.

Neuropharmacology. 2014 Apr;79:668-78. doi: 10.1016/j.neuropharm.2014.01.023. Epub 2014 Jan 24.


IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor.

Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM, Zlokovic BV.

J Neurosci. 2005 Dec 14;25(50):11495-503.


Apolipoprotein E isoform-specific effects on lipoprotein receptor processing.

Bachmeier C, Shackleton B, Ojo J, Paris D, Mullan M, Crawford F.

Neuromolecular Med. 2014 Dec;16(4):686-96.


Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition.

Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA.

J Alzheimers Dis. 2009;17(3):553-70. doi: 10.3233/JAD-2009-1074.


Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2016;49(2):287-300. doi: 10.3233/JAD-150350.


Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease.

Deane R, Bell RD, Sagare A, Zlokovic BV.

CNS Neurol Disord Drug Targets. 2009 Mar;8(1):16-30. Review.


Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier.

Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA.

J Neuroinflammation. 2012 Jun 29;9:150. doi: 10.1186/1742-2094-9-150.


Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway.

Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH.

J Clin Invest. 2000 Nov;106(9):1159-66.


Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.

LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R, Zlokovic BV.

J Neurosci Methods. 2004 Sep 30;138(1-2):233-42.


A multifaceted role for apoE in the clearance of beta-amyloid across the blood-brain barrier.

Bachmeier C, Paris D, Beaulieu-Abdelahad D, Mouzon B, Mullan M, Crawford F.

Neurodegener Dis. 2013;11(1):13-21. Epub 2012 May 8.


Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.

Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV.

J Clin Invest. 1998 Aug 15;102(4):734-43.


Amyloid-β protein modulates the perivascular clearance of neuronal apolipoprotein E in mouse models of Alzheimer's disease.

Rolyan H, Feike AC, Upadhaya AR, Waha A, Van Dooren T, Haass C, Birkenmeier G, Pietrzik CU, Van Leuven F, Thal DR.

J Neural Transm (Vienna). 2011 May;118(5):699-712. doi: 10.1007/s00702-010-0572-7. Epub 2011 Jan 6.


Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease.

Deane R, Zlokovic BV.

Curr Alzheimer Res. 2007 Apr;4(2):191-7. Review.


Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier.

Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D.

Mol Cell Neurosci. 2013 Sep;56:255-62. doi: 10.1016/j.mcn.2013.06.004. Epub 2013 Jul 3.


Supplemental Content

Support Center